CN113679794A - Uric acid-reducing sunflower disc composition and preparation method thereof - Google Patents
Uric acid-reducing sunflower disc composition and preparation method thereof Download PDFInfo
- Publication number
- CN113679794A CN113679794A CN202111145373.4A CN202111145373A CN113679794A CN 113679794 A CN113679794 A CN 113679794A CN 202111145373 A CN202111145373 A CN 202111145373A CN 113679794 A CN113679794 A CN 113679794A
- Authority
- CN
- China
- Prior art keywords
- parts
- uric acid
- sunflower disc
- sieving
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 235000003222 Helianthus annuus Nutrition 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 241000208818 Helianthus Species 0.000 title claims description 34
- 238000002360 preparation method Methods 0.000 title claims description 12
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 31
- 229940116269 uric acid Drugs 0.000 claims abstract description 31
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 20
- 235000007542 Cichorium intybus Nutrition 0.000 claims abstract description 18
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 17
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 16
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 16
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 13
- 229920002752 Konjac Polymers 0.000 claims abstract description 13
- 235000010485 konjac Nutrition 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 239000000843 powder Substances 0.000 claims description 24
- 238000000605 extraction Methods 0.000 claims description 20
- 238000007873 sieving Methods 0.000 claims description 19
- 241000723343 Cichorium Species 0.000 claims description 17
- 241000157835 Gardenia Species 0.000 claims description 16
- 241000245665 Taraxacum Species 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 15
- 238000001291 vacuum drying Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000008213 purified water Substances 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 25
- 239000003814 drug Substances 0.000 abstract description 16
- 230000008961 swelling Effects 0.000 abstract description 15
- 208000002193 Pain Diseases 0.000 abstract description 7
- 230000007774 longterm Effects 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 4
- 240000001949 Taraxacum officinale Species 0.000 abstract description 2
- 244000020551 Helianthus annuus Species 0.000 abstract 3
- 244000298479 Cichorium intybus Species 0.000 abstract 1
- 244000111489 Gardenia augusta Species 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 18
- 230000001603 reducing effect Effects 0.000 description 16
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 15
- 201000001431 Hyperuricemia Diseases 0.000 description 15
- 201000005569 Gout Diseases 0.000 description 12
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 8
- 208000004880 Polyuria Diseases 0.000 description 7
- 230000035619 diuresis Effects 0.000 description 7
- 210000001503 joint Anatomy 0.000 description 6
- 229960003459 allopurinol Drugs 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 229960001338 colchicine Drugs 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 244000247812 Amorphophallus rivieri Species 0.000 description 3
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 210000000544 articulatio talocruralis Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000000252 konjac Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 244000268590 Euryale ferox Species 0.000 description 2
- 235000006487 Euryale ferox Nutrition 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 208000034170 Disorder of purine metabolism Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 208000016839 purine metabolism disease Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a uric acid-reducing sunflower disc composition which is mainly prepared from the following raw material components in parts by mass: 20-30 parts of sunflower disc, 12-20 parts of chicory root, 10-18 parts of gardenia, 10-18 parts of dandelion, 8-16 parts of kudzu root, 6-12 parts of coix seed, 6-12 parts of konjak, 6-12 parts of red date and 1-5 parts of chitosan oligosaccharide. The uric acid-reducing sunflower disc composition can effectively reduce uric acid, has the functions of relieving swelling and pain, can integrally condition a human body, is a traditional Chinese medicine component, has relatively small side effect and is suitable for long-term use.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, and in particular relates to a uric acid-reducing sunflower disc composition and a preparation method thereof.
Background
In recent years, the incidence of hyperuricemia in Chinese population is also on the straight line and in the trend of younger development, and the incidence of hyperuricemia in China is increased by about 10 times since 1996-2006, and the hyperuricemia becomes the clinical 'fourth highest' after hypertension, hyperlipidemia and hyperglycemia. One of the main effects of long-term hyperuricemia on the human body is gout caused by deposition of urate crystals on joints and kidneys. Hyperuricemia is an important biochemical basis for gout, and about 5% to 12% of patients with hyperuricemia develop gout. Gout not only can invade bones and joints, but also easily affects the kidney and cardiovascular system.
Gout is a disease caused by a disorder of purine metabolism and/or a decrease in uric acid excretion. Hyperuricemia results from elevated blood uric acid levels due to excessive purine uptake and decreased excretion. After such hyperuricemia continues to occur, urate crystals are deposited in or around joints, which causes so-called gout symptoms such as acute arthritis attack, gout nodules, joint dysfunction, joint deformity, and the like, and further causes various complications such as renal dysfunction, vascular disorder, and the like.
At present, western medicines lack powerful drugs in the aspect of treatment of hyperuricemia, allopurinol, colchicine and the like which inhibit the generation of uric acid only simply inhibit but not fundamentally improve purine metabolism, and liver and kidney toxicity and blood system damage exist, so that the western medicines are not suitable for long-term use. Therefore, the search for a new safe and effective functional component for reducing uric acid has important practical significance and application value, and the treatment advantages of the traditional Chinese medicinal materials in the aspect are increasingly prominent.
Sunflower disc: is cold in nature and sweet in flavor, enters liver meridian, and has the effects of clearing heat, calming liver, relieving pain, stopping bleeding and the like.
Chicory root: slightly bitter, salty and cool, enter liver, gallbladder and stomach meridians, clear liver heat and promote bile flow, invigorate stomach and promote digestion, induce diuresis and reduce edema.
Gardenia: bitter and cold, entering heart, lung and triple energizer meridians, purging fire and relieving restlessness, clearing heat and promoting diuresis, cooling blood and removing toxicity.
Dandelion: bitter, sweet and cold, entering liver and stomach meridians, clearing away heat and toxic material, dispersing swelling and dissipating nodulation, inducing diuresis for treating stranguria.
Coix seed: sweet, bland and cool, enter spleen, stomach and lung channels, promote diuresis and excrete dampness, invigorate spleen to stop diarrhea, remove arthralgia, expel pus, detoxify and dissipate stagnation;
kudzu root: sweet, pungent and cool, enter spleen, stomach and lung meridians, release muscles and allay fever, promote the production of body fluid to quench thirst, promote eruption, raise yang to arrest diarrhea, clear and activate the channels and collaterals, and relieve alcoholism.
Konjak: it is cold in nature and mild in taste, and can relieve swelling and remove toxicity when used as a medicine.
Red dates: warm in nature and sweet in taste, and has the effects of tonifying qi and blood, strengthening spleen and stomach and dispelling wind.
Chitosan oligosaccharide: only cationic alkaline amino-oligosaccharide with positive charge in nature can neutralize redundant acid in vivo, improve weakly acidic constitution, and inhibit activity of Huangheu oxidase in chronic hyperuricemia.
The patent with the application number of 201811509838.8 discloses a sunflower disc-gordon euryale seed-kudzuvine root compound which consists of a sunflower disc, gordon euryale seed and kudzuvine root, has no obvious traditional Chinese medicine components for promoting urination and reducing swelling, is not beneficial to the treatment of hyperuricemia, has few symptoms-treating medicines and takes effect slowly.
Disclosure of Invention
The invention provides a uric acid-reducing sunflower disc composition and a preparation method thereof, the uric acid-reducing sunflower disc composition can effectively reduce uric acid, has the effects of relieving swelling and pain, can integrally condition a human body, and has relatively small side effect.
The invention is realized by the following technical scheme:
the sunflower disc composition for reducing uric acid is mainly prepared from the following raw material components in parts by mass:
20-30 parts of sunflower disc, 12-20 parts of chicory root, 10-18 parts of gardenia, 10-18 parts of dandelion, 8-16 parts of kudzu root, 6-12 parts of coix seed, 6-12 parts of konjak, 6-12 parts of red date and 1-5 parts of chitosan oligosaccharide.
Preferably, the sunflower disc composition for reducing uric acid is mainly prepared from the following raw material components in parts by mass:
25 parts of sunflower disc, 16 parts of chicory root, 13 parts of gardenia, 12 parts of dandelion, 12 parts of kudzu root, 8 parts of coix seed, 6 parts of konjak, 6 parts of red date and 2 parts of chitosan oligosaccharide.
A preparation method of a uric acid-reducing sunflower disc composition comprises the following steps:
(1) placing sunflower disc, chicory root, gardenia, dandelion and kudzu root into a multifunctional extraction tank, then adding ethanol, carrying out hot reflux extraction at 60-80 ℃ for more than 2 times, wherein the extraction time is 1.5-3h each time, then combining and filtering the extracting solutions obtained each time, then removing the ethanol to leave a filtrate, sieving the obtained filtrate, carrying out vacuum drying at the pressure of 0.06-0.08Pa and the temperature of 60-80 ℃ for 3-4h, and then sieving the filtrate by a sieve of 80-100 meshes to prepare dry powder for later use;
the amount of the ethanol is 8-12 times of the total mass of the sunflower disc, the chicory root, the gardenia, the dandelion and the kudzu root;
(2) placing Coicis semen, fructus Jujubae and rhizoma Amorphophalli in multifunctional extraction tank, adding purified water, standing completely, heating at 80-100 deg.C for 1-2 hr, and filtering; the obtained filtrate is used; adding purified water into the obtained filter residue, standing completely, heating at 80-100 deg.C for 1-2 hr, and filtering to obtain filtrate; sieving the filtrates, vacuum drying at 60-80 deg.C under 0.06-0.08Pa for 3-4 hr, and sieving with 80-100 mesh sieve to obtain dry powder;
(3) sieving chitosan oligosaccharide with 80-100 mesh sieve;
(4) and (3) uniformly mixing the dry powder prepared in the step (1), the dry powder prepared in the step (2) and the chitosan oligosaccharide powder prepared in the step (3).
When in use, the composition can be added with adjuvants to make into powder, pill, tablet, granule or capsule.
The ethanol is 70-85 parts of ethanol.
The principle is as follows:
the sunflower disc can clear heat and calm the liver, and the chicory root can induce diuresis to reduce edema, so that the effect of clearing liver and benefiting gallbladder, inducing diuresis to reduce edema can be achieved by the sunflower disc and the chicory root which are used together, and the effects of removing uric acid and treating both principal and secondary aspects are achieved; the gardenia, the dandelion, the coix seed and the konjak can clear heat and sterilize, reduce swelling and eliminate stagnation, promote diuresis and eliminate dampness, are used as ministerial drugs together, assist the monarch drugs to enhance the efficacy of dispelling heat and promoting urination and relieve the red swelling caused by hyperuricemia; the kudzu vine root can clear and activate the channels and collaterals, the red date can tonify qi and nourish blood, and the kudzu vine root and the red date are used as adjuvant drugs to assist monarch drugs and ministerial drugs in enhancing the effect of eliminating evil; the chitosan oligosaccharide has effect in inhibiting activity of chronic hyperuricemia heynohuang oxidase, and can be used for regulating effect of other drugs to eliminate pathogenic factors. The uric acid reducing composition has strict compatibility and gives consideration to both principal and secondary aspects.
By relaxing bowel and dredging digestive function, on the basis of relaxing bowel, the traditional Chinese medicine composition has the effects of clearing heat and purging fire, clearing heat and reducing phlegm, promoting excretion, eliminating disease symptoms caused by internal fire and the like due to moisture in a body, restoring absorption and excretion balance in the body, particularly restoring uric acid excretion balance, improving liver and kidney functions, reducing deposition of urate on joints and kidney parts, restoring body functions, preparing a large amount of leukocytes in immune cells to phagocytose uric acid crystals, eliminating various inflammations, reducing arthritis caused by hyperuricemia, and fundamentally controlling gout. Meanwhile, the stomach-invigorating tea has the effects of tonifying middle-jiao and invigorating stomach, helping digestion and removing greasiness, enhancing appetite, improving digestion capacity, and tonifying spleen and stomach, so that various vitamins and trace elements are absorbed, and the effects of treating both principal and secondary aspects of diseases are achieved from inside to outside.
Compared with the prior art, the invention has the beneficial effects that:
the uric acid-reducing sunflower disc composition can effectively reduce uric acid, has the functions of relieving swelling and pain, can integrally condition a human body, is a traditional Chinese medicine component, has relatively small side effect and is suitable for long-term use.
Detailed Description
The invention is further illustrated but is not intended to be limited by the following examples
Example 1
The composition for reducing uric acid is prepared from the following raw materials in parts by mass:
20g of sunflower disc, 20g of chicory root, 18g of gardenia, 10g of dandelion, 8g of kudzu root, 6g of coix seed, 6g of konjak, 6g of red date and 1g of chitosan oligosaccharide.
The preparation method of the uric acid reducing composition comprises the following steps:
s1, putting the sunflower disc, the chicory root, the gardenia, the dandelion and the radix puerariae in the formula ratio into a multifunctional extraction tank, adding 70 parts of 8 times of ethanol, carrying out hot reflux extraction for 2 times, wherein the extraction time is 1.5h each time, combining the extracting solutions, filtering the extracting solutions by using a 100-mesh sieve, recovering the ethanol, carrying out vacuum concentration on the filtrate, carrying out vacuum drying at the pressure of 0.08Pa and the temperature of 60 ℃ for 4h, and sieving the dried extract by using a 80-mesh sieve to prepare dry powder for later use;
s2, putting the coix seeds, the red dates and the konjac in the formula ratio into a multifunctional extraction tank, adding 8-12 times of purified water, completely standing, heating to 100 ℃, extracting for 1h, filtering, extracting filter residues for 1h under the same condition, combining the two extracting solutions, sieving through a 100-mesh sieve, performing vacuum concentration under the pressure of 0.08Pa, the temperature of 60 ℃ and the time of 4h, performing vacuum drying under the pressure of 0.08Pa, the temperature of 60 ℃ and the time of 4h, and sieving the dried extract through a 80-mesh sieve to prepare dry powder for later use;
s3, sieving the chitosan oligosaccharide with the formula ratio by a sieve of 80 meshes for later use
S4, mixing the dried powder of S1 and S2 with the chitosan oligosaccharide sieved by S3, adding pharmaceutically acceptable adjuvants, and making into powder, pill, tablet, granule or capsule.
Example 2
The composition for reducing uric acid is prepared from the following raw materials in parts by mass:
25g of sunflower disc, 16g of chicory root, 13g of gardenia, 12g of dandelion, 12g of kudzu root, 8g of coix seed, 6g of konjak, 6g of red date and 2g of chitosan oligosaccharide.
The preparation method of the uric acid reducing composition comprises the following steps:
s1, putting the sunflower disc, the chicory root, the gardenia, the dandelion and the radix puerariae in the formula ratio into a multifunctional extraction tank, adding 10 times of 80 parts of ethanol, carrying out hot reflux extraction for 2 times, wherein the extraction time is 1.5h each time, combining the extracting solutions, filtering the extracting solutions by using a 100-mesh sieve, recovering the ethanol, carrying out vacuum concentration on the filtrate, carrying out vacuum drying at the pressure of 0.08Pa and the temperature of 70 ℃ for 3.5h, and sieving the dried extract by using a 80-mesh sieve to prepare dry powder for later use;
s2, putting the coix seeds, the red dates and the konjac in the formula ratio into a multifunctional extraction tank, adding 10 times of purified water, heating to 100 ℃ after completely standing, extracting for 1h, filtering, extracting filter residues for 1h under the same condition, combining the two extracting solutions, filtering through a 100-mesh sieve, concentrating in vacuum at the pressure of 0.08Pa and the temperature of 70 ℃ for 3.5h, drying in vacuum at the pressure of 0.08Pa and the temperature of 70 ℃ for 3.5h, and sieving the dried extract through a 80-mesh sieve to prepare dry powder for later use;
s3, sieving the chitosan oligosaccharide with the formula ratio by a sieve of 80 meshes for later use
S4, mixing the dried powder of S1 and S2 with the chitosan oligosaccharide sieved by S3, adding pharmaceutically acceptable adjuvants, and making into powder, pill, tablet, granule or capsule.
Example 3
The composition for reducing uric acid is prepared from the following raw materials in parts by mass:
30g of sunflower disc, 12g of chicory root, 10g of gardenia, 18g of dandelion, 16g of kudzu root, 12g of coix seed, 12g of konjak, 12g of red date and 5g of chitosan oligosaccharide.
The preparation method of the uric acid reducing composition comprises the following steps:
s1, putting the sunflower disc, the chicory root, the gardenia, the dandelion and the radix puerariae in the formula ratio into a multifunctional extraction tank, adding 12 times of 85 parts of ethanol, carrying out hot reflux extraction for 2 times, wherein the extraction time is 1.5h each time, combining the extracting solutions, filtering the extracting solutions by using a 100-mesh sieve, recovering the ethanol, carrying out vacuum concentration on the filtrate, carrying out vacuum drying at the pressure of 0.08Pa and the temperature of 80 ℃ for 3h, and sieving the dried extract by using a 80-mesh sieve to prepare dry powder for later use;
s2, putting the coix seeds, the red dates and the konjac in the formula ratio into a multifunctional extraction tank, adding 12 times of purified water, heating to 100 ℃ after completely standing, extracting for 1h, filtering, extracting filter residues for 1h under the same condition, combining the two extracting solutions, filtering through a 100-mesh sieve, concentrating in vacuum at the pressure of 0.08Pa and the temperature of 80 ℃ for 3h, drying in vacuum at the pressure of 0.08Pa and the temperature of 80 ℃ for 3h, and filtering the dried extract through a 80-mesh sieve to prepare dry powder for later use;
s3, sieving the chitosan oligosaccharide with the formula ratio by a sieve of 80 meshes for later use
S4, mixing the dried powder of S1 and S2 with the chitosan oligosaccharide sieved by S3, adding pharmaceutically acceptable adjuvants, and making into powder, pill, tablet, granule or capsule.
Efficacy evaluation test
1. Experiment grouping
70 rats were randomly divided into 7 groups of 10 rats each, a blank control group, a model group, an experimental group (examples 1-3), an experimental control group (colchicine and allopurinol)
Colchicine and allopurinol are common medicines for reducing uric acid and treating gout at present, but have damage to liver and kidney toxicity and a blood system, and are not suitable for long-term use. The composition disclosed by the invention is a traditional Chinese medicine component, can effectively reduce uric acid, has the effects of relieving swelling and pain, has small toxic and side effects, and is suitable for long-term use.
2. Experimental procedures
The models, experimental groups and control groups were fed daily with adenine (200 mg/kg. d) for 7 days, following the Coderre classical protocol. On the 8 th day, after the hyperuricemia model building is successful, except for the blank group, the rats are anesthetized in other groups, a puncture point is arranged at the rear part of the outer side of the right ankle joint of each rat, 25mg/ml sodium urate solution is injected into the ankle joint cavity to form an acute gouty arthritis model, and the drug is respectively fed after 7 days of model building. Physiological saline was administered to the blank control group, example 1 of the experimental group was administered in (95 × 0.018)/0.2kg, i.e., 8.55g/kg, example 2 was administered in (100 × 0.018)/0.2kg, i.e., 9g/kg, example 3 was administered in (127 × 0.018)/0.2kg, i.e., 11.43g/kg (conversion was made according to the body surface area ratio of 0.018:1 between rats and humans to determine the standard body weight rat composition dose), the allopurinol group was administered in 27mg/kg (allopurinol tablet clinical dose was 300mg, conversion was made according to the body surface area ratio of 0.018:1 between rats and humans to determine the standard body weight rat dose was (300mg × 0.018)/0.2kg, i.e., 27mg/kg), the colchicine group was administered in 0.09mg/kg (colchicine clinical dose was 1.0mg, according to the body surface area ratio of 0.018:1 between rats and humans, the dose of the rat is (1.0 mg. times.0.018)/0.2 kg, i.e., 0.09mg/kg, in terms of the standard body weight.
3. Statistical analysis
Analyzing the experimental data of each group of experimental mice by adopting SPSS19.0 software, wherein the experimental data are expressed by X +/-S, and the multiple groups are analyzed by adopting one-factor variance, so that the P <0.05 has obvious difference; p <0.01 has a very significant difference.
4. Results of the experiment
Effect on swelling of rat joints
After the model is formed, measuring the circumference of the right ankle joint of the rat 4h, 8h, 12h, 24h and 48h after the model is formed, and calculating the swelling degree. As can be seen from Table 1, the blank control group was significantly different from the model group and the administration groups at each time point, indicating that the molding was successful. After 4h of molding, the degree of swelling of the joints in the model group was higher than that in the experimental group (example 1, example 2 and example 3) and the experimental control group (colchicine group and allopurinol group) of the invention, but the experimental control group had no statistical difference. After 8h of modeling, compared with the model group, the experimental group and the experimental control group of the invention both relieve the joint swelling degree to a certain extent, wherein the example 2 of the invention has very significant difference with the colchicine group and the allopurinol group. After 12h of modeling, the experimental group has the obvious tendency of relieving the joint swelling, the effect is close to that of a colchicine group and an allopurinol group, and the effect of the experimental group after 48h of modeling is equivalent to that of the colchicine group and is superior to that of the allopurinol group. The results prove that the uric acid-reducing sunflower disc composition has the effects of relieving swelling and pain in the acute gout attack process. Table 1 comparison of swelling degree of joint of rats (x ± s, n ═ 10)
Note: comparison with model group of P <0.01, P <0.05
4.2 Effect of uric acid lowering compositions on rat blood uric acid levels
After half an hour after the administration on day 7, serum was taken from each group of rats and serum uric acid concentration was measured. As can be seen from Table 2, the blood uric acid level in the model group is significantly higher than that in the blank group, which indicates that the serum uric acid concentration of the rat is significantly increased after the model is made. The blood uric acid water averages of the examples 1-3, the colchicine group and the allopurinol group are lower than those of the model group, wherein the example 2 group and the allopurinol group have very obvious differences compared with the model group, and the examples 1, 2 and the colchicine group have obvious differences compared with the model group, which shows that the example of the invention can effectively reduce the blood uric acid concentration of rats.
Table 2 comparison of serum uric acid levels in rats of each group (x ± s, n ═ 10)
Note: comparison with model group of P <0.01, P <0.05
And (4) conclusion: the invention has obvious effect of reducing serum uric acid and has the effects of relieving swelling and pain in the acute gout attack process.
Claims (5)
1. The uric acid-reducing sunflower disc composition is characterized in that: the composite material is mainly prepared from the following raw materials in parts by mass:
20-30 parts of sunflower disc, 12-20 parts of chicory root, 10-18 parts of gardenia, 10-18 parts of dandelion, 8-16 parts of kudzu root, 6-12 parts of coix seed, 6-12 parts of konjak, 6-12 parts of red date and 1-5 parts of chitosan oligosaccharide.
2. The uric acid lowering sunflower disc composition according to claim 1, wherein the composition comprises: the composite material is mainly prepared from the following raw materials in parts by mass: 25 parts of sunflower disc, 16 parts of chicory root, 13 parts of gardenia, 12 parts of dandelion, 12 parts of kudzu root, 8 parts of coix seed, 6 parts of konjak, 6 parts of red date and 2 parts of chitosan oligosaccharide.
3. A method for preparing the uric acid-lowering sunflower disc composition according to claim 1 or 2, wherein the method comprises the following steps: the method comprises the following steps:
(1) placing sunflower disc, chicory root, gardenia, dandelion and kudzu root into a multifunctional extraction tank, then adding ethanol, carrying out hot reflux extraction at 60-80 ℃ for more than 2 times, wherein the extraction time is 1.5-3h each time, then combining and filtering the extracting solutions obtained each time, then removing the ethanol to leave a filtrate, sieving the obtained filtrate, carrying out vacuum drying at the pressure of 0.06-0.08Pa and the temperature of 60-80 ℃ for 3-4h, and then sieving the filtrate by a sieve of 80-100 meshes to prepare dry powder for later use;
the amount of the ethanol is 8-12 times of the total mass of the sunflower disc, the chicory root, the gardenia, the dandelion and the kudzu root;
(2) placing Coicis semen, fructus Jujubae and rhizoma Amorphophalli in multifunctional extraction tank, adding purified water, standing completely, heating at 80-100 deg.C for 1-2 hr, and filtering; the obtained filtrate is used; adding purified water into the obtained filter residue, standing completely, heating at 80-100 deg.C for 1-2 hr, and filtering to obtain filtrate; sieving the filtrates, vacuum drying at 60-80 deg.C under 0.06-0.08Pa for 3-4 hr, and sieving with 80-100 mesh sieve to obtain dry powder;
(3) sieving chitosan oligosaccharide with 80-100 mesh sieve;
(4) and (3) uniformly mixing the dry powder prepared in the step (1), the dry powder prepared in the step (2) and the chitosan oligosaccharide powder prepared in the step (3).
4. The preparation method of the uric acid-lowering sunflower disc composition according to claim 3, wherein the preparation method comprises the following steps: when in use, the composition can be added with adjuvants to make into powder, pill, tablet, granule or capsule.
5. The preparation method of the uric acid-lowering sunflower disc composition according to claim 4, wherein the preparation method comprises the following steps: the ethanol in the step (1) is 70-85% by mass.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111145373.4A CN113679794A (en) | 2021-09-28 | 2021-09-28 | Uric acid-reducing sunflower disc composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111145373.4A CN113679794A (en) | 2021-09-28 | 2021-09-28 | Uric acid-reducing sunflower disc composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113679794A true CN113679794A (en) | 2021-11-23 |
Family
ID=78587265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111145373.4A Pending CN113679794A (en) | 2021-09-28 | 2021-09-28 | Uric acid-reducing sunflower disc composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113679794A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114027432A (en) * | 2021-12-17 | 2022-02-11 | 广东长昊药业股份有限公司 | Uric acid-removing gout-preventing sunflower disc solid beverage and preparation method and application thereof |
| CN114190503A (en) * | 2021-12-15 | 2022-03-18 | 哈尔滨健领医疗科技有限公司 | Solid beverage for reducing uric acid and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106668657A (en) * | 2017-03-03 | 2017-05-17 | 孙龙喜 | Beverage capable of lowering uric acid and lipid and preparation method of beverage |
| CN113318201A (en) * | 2021-06-15 | 2021-08-31 | 湖南琥茗生物科技有限公司 | Health food for reducing uric acid and preparation method thereof |
-
2021
- 2021-09-28 CN CN202111145373.4A patent/CN113679794A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106668657A (en) * | 2017-03-03 | 2017-05-17 | 孙龙喜 | Beverage capable of lowering uric acid and lipid and preparation method of beverage |
| CN113318201A (en) * | 2021-06-15 | 2021-08-31 | 湖南琥茗生物科技有限公司 | Health food for reducing uric acid and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 廖婷等: "中医药治疗痛风性关节炎的研究进展", 《黑龙江科学》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114190503A (en) * | 2021-12-15 | 2022-03-18 | 哈尔滨健领医疗科技有限公司 | Solid beverage for reducing uric acid and preparation method thereof |
| CN114027432A (en) * | 2021-12-17 | 2022-02-11 | 广东长昊药业股份有限公司 | Uric acid-removing gout-preventing sunflower disc solid beverage and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023512529A (en) | Chinese herbal compound prescription with lung detoxification function and its application | |
| CN101049424B (en) | Medication for treating infection in respiratory system | |
| CN113679794A (en) | Uric acid-reducing sunflower disc composition and preparation method thereof | |
| CN114470114B (en) | Application of Mailuoshutong preparation in preparation of medicine for treating constipation | |
| CN103751579B (en) | Treatment nasopharyngeal carcinoma radiotherapy pharmaceutical composition causing oral mucositis and preparation method thereof | |
| CN102847061B (en) | Traditional Chinese medicine preparation for treating pediatric viral myocarditis and preparation method thereof | |
| CN106075020A (en) | A kind of lucid ganoderma complex granule with treatment diabetes effect | |
| CN102166309B (en) | Preparation method of traditional Chinese medicine for curing middle energizer intrinsic heat type hyperthyroidism | |
| CN103520652B (en) | Traditional Chinese medicine composition for treating liver cancer | |
| CN103169900B (en) | Chinese herba preparation for treating gout | |
| CN1233364C (en) | Chinese medicine for treating digestive ulcerating sore and its preparation method | |
| CN110946950A (en) | A Chinese medicinal composition for treating senile vascular dementia, and its preparation method | |
| CN1706467A (en) | Plaster for treating bronchitis | |
| CN1899385A (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN114588233B (en) | Composition for treating acute gout | |
| CN101757407B (en) | Traditional Chinese medicine composition for treating asthma and preparation method thereof | |
| CN116350731B (en) | Formula for clearing heat, removing dampness and relieving arthralgia as well as preparation and application thereof | |
| CN107913389A (en) | A kind of Chinese medicine composition for treating Thyroid Gland Swell and preparation method thereof | |
| CN101380414B (en) | Traditional Chinese medicine composition for treating gout and hyperuricemia and preparation method thereof | |
| CN110859945B (en) | Capsule for preventing and treating ankylosing spondylitis and preparation method thereof | |
| CN104784567B (en) | A kind of pharmaceutical composition for the treatment of urinary system infection | |
| KR20080005592A (en) | Use of amorphophallus rivieri durieu and extract thereof in the manufacture of a medicament for treating acute, chronic bronchitis | |
| CN105477384A (en) | Traditional Chinese medicine composition capable of reducing blood pressure and preparation method of composition | |
| CN1132600C (en) | Baichun Prepn. for treating women's pelvic infection | |
| CN1175860C (en) | Complete granule for treating hepatocirrhosis and liver ascites and its prepn. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211123 |